These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 30256790)

  • 1. Prediction and validation of the structural features of Ov58GPCR, an immunogenic determinant of Onchocerca volvulus.
    Shey RA; Ghogomu SM; Njume FN; Gainkam LOT; Poelvoorde P; Mutesa L; Robert A; Humblet P; Munyampundu JP; Kamgno J; Lelubre C; Vanhamme L; Souopgui J
    PLoS One; 2018; 13(9):e0202915. PubMed ID: 30256790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection.
    Soboslay PT; Geiger SM; Weiss N; Banla M; Lüder CG; Dreweck CM; Batchassi E; Boatin BA; Stadler A; Schulz-Key H
    Immunology; 1997 Apr; 90(4):592-9. PubMed ID: 9176114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy.
    Mai CS; Hamm DM; Banla M; Agossou A; Schulz-Key H; Heuschkel C; Soboslay PT
    Clin Exp Immunol; 2007 Mar; 147(3):504-12. PubMed ID: 17302900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of ivermectin treatment on the antibody response to antigens of Onchocerca volvulus.
    Gillespie AJ; Lustigman S; Rivas-Alcala AR; Bradley JE
    Trans R Soc Trop Med Hyg; 1994; 88(4):456-60. PubMed ID: 7570844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent updates on onchocerciasis: diagnosis and treatment.
    Udall DN
    Clin Infect Dis; 2007 Jan; 44(1):53-60. PubMed ID: 17143815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of onchocerciasis seroprevalence in Bioko Island (Equatorial Guinea) after years of disease control programmes.
    Hernández-González A; Moya L; Perteguer MJ; Herrador Z; Nguema R; Nguema J; Aparicio P; Benito A; Gárate T
    Parasit Vectors; 2016 Sep; 9(1):509. PubMed ID: 27645887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling Neglected Tropical Diseases diagnostics: the sensitivity of skin snips for Onchocerca volvulus in near elimination and surveillance settings.
    Bottomley C; Isham V; Vivas-Martínez S; Kuesel AC; Attah SK; Opoku NO; Lustigman S; Walker M; Basáñez MG
    Parasit Vectors; 2016 Jun; 9(1):343. PubMed ID: 27301567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Onchocerca volvulus-specific antibody and cellular responses in onchocerciasis patients treated annually with ivermectin for 30 years and exposed to parasite transmission in central Togo.
    Johanns SI; Gantin RG; Wangala B; Komlan K; Halatoko WA; Banla M; Karabou P; Luty AJ; Schulz-Key H; Köhler C; Soboslay PT
    PLoS Negl Trop Dis; 2022 May; 16(5):e0010340. PubMed ID: 35503786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin G subclass responses of children during infection with Onchocerca volvulus.
    Gbakima AA; Nutman TB; Bradley JE; McReynolds LA; Winget MD; Hong Y; Scott AL
    Clin Diagn Lab Immunol; 1996 Jan; 3(1):98-104. PubMed ID: 8770512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection.
    Soboslay PT; Lüder CG; Hoffmann WH; Michaelis I; Helling G; Heuschkel C; Dreweck CM; Blanke CH; Pritze S; Banla M
    Clin Exp Immunol; 1994 May; 96(2):238-44. PubMed ID: 8187332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A community-based cross-sectional study of the epidemiology of onchocerciasis in unmapped villages for community directed treatment with ivermectin in Jimma Zone, southwestern Ethiopia.
    Dana D; Debalke S; Mekonnen Z; Kassahun W; Suleman S; Getahun K; Yewhalaw D
    BMC Public Health; 2015 Jul; 15():595. PubMed ID: 26130117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment and monitoring of onchocerciasis in Latin America.
    Rodríguez-Pérez MA; Unnasch TR; Real-Najarro O
    Adv Parasitol; 2011; 77():175-226. PubMed ID: 22137585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune recognition of Onchocerca volvulus proteins in the human host and animal models of onchocerciasis.
    Manchang TK; Ajonina-Ekoti I; Ndjonka D; Eisenbarth A; Achukwi MD; Renz A; Brattig NW; Liebau E; Breloer M
    J Helminthol; 2015 May; 89(3):375-86. PubMed ID: 24721822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+-dependent immunity to Onchocerca volvulus third-stage larvae in humans and the mouse vaccination model: common ground and distinctions.
    Lustigman S; MacDonald AJ; Abraham D
    Int J Parasitol; 2003 Sep; 33(11):1161-71. PubMed ID: 13678632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary evaluations of 3-dimensional human skin models for their ability to facilitate in vitro the long-term development of the debilitating obligatory human parasite Onchocerca volvulus.
    Malkmus C; Jawahar S; Tricoche N; Lustigman S; Hansmann J
    PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008503. PubMed ID: 33151944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans.
    George PJ; Hess JA; Jain S; Patton JB; Zhan T; Tricoche N; Zhan B; Bottazzi ME; Hotez PJ; Abraham D; Lustigman S
    PLoS Negl Trop Dis; 2019 Sep; 13(9):e0007730. PubMed ID: 31525197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status.
    Mahdy MAK; Abdul-Ghani R; Abdulrahman TAA; Al-Eryani SMA; Al-Mekhlafi AM; Alhaidari SAA; Azazy AA
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006329. PubMed ID: 29505580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization and immune recognition of the extracellular superoxide dismutase from the human pathogenic parasite Onchocerca volvulus (OvEC-SOD).
    Ajonina-Ekoti I; Ndjonka D; Tanyi MK; Wilbertz M; Younis AE; Boursou D; Kurosinski MA; Eberle R; Lüersen K; Perbandt M; Breloer M; Brattig NW; Liebau E
    Acta Trop; 2012 Oct; 124(1):15-26. PubMed ID: 22677600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Onchocerca volvulus cysteine proteinase inhibitor, Ov-CPI-2, is a target of protective antibody response that increases with age.
    Cho-Ngwa F; Liu J; Lustigman S
    PLoS Negl Trop Dis; 2010 Aug; 4(8):e800. PubMed ID: 20808763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment.
    Bourguinat C; Pion SD; Kamgno J; Gardon J; Duke BO; Boussinesq M; Prichard RK
    PLoS Negl Trop Dis; 2007 Aug; 1(1):e72. PubMed ID: 17989786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.